{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:18:26Z","timestamp":1761718706194,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T00:00:00Z","timestamp":1531353600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00405-018-5058-5","type":"journal-article","created":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T04:02:16Z","timestamp":1531368136000},"page":"2341-2347","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors"],"prefix":"10.1007","volume":"275","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6986-9148","authenticated-orcid":false,"given":"Jefferson da Rocha","family":"Ten\u00f3rio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leorik Pereira","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00edlia Gabriela de Aguiar","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thalita","family":"Santana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George Jo\u00e3o Ferreira","family":"do Nascimento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Paula Veras","family":"Sobral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,12]]},"reference":[{"issue":"1","key":"5058_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12105-017-0795-0","volume":"11","author":"RR Seethala","year":"2017","unstructured":"Seethala RR, Stenman G (2017) Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: tumors of the salivary gland. Head Neck Pathol 11(1):55\u201367. \n                    https:\/\/doi.org\/10.1007\/s12105-017-0795-0","journal-title":"Head Neck Pathol"},{"key":"5058_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.oraloncology.2017.01.004","volume":"66","author":"MH Valstar","year":"2017","unstructured":"Valstar MH, de Ridder M, van den Broek EC, Stuiver MM, van Dijk BAC, van Velthuysen MLF, Balm AJM, Smeele LE (2017) Salivary gland pleomorphic adenoma in the Netherlands: a nationwide observational study of primary tumor incidence, malignant transformation, recurrence, and risk factors for recurrence. Oral Oncol 66:93\u201399. \n                    https:\/\/doi.org\/10.1016\/j.oraloncology.2017.01.004","journal-title":"Oral Oncol"},{"key":"5058_CR3","first-page":"51","volume":"28","author":"A Andisheh-Tadbir","year":"2016","unstructured":"Andisheh-Tadbir A, Dehghani-Nazhvani A, Ashraf MJ, Khademi B, Mirhadi H, Torabi-Ardekani S (2016) MTA1 expression in benign and malignant salivary gland tumors. Iran J Otorhinolaryngol 28:51\u201359","journal-title":"Iran J Otorhinolaryngol"},{"issue":"3","key":"5058_CR4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s12105-012-0417-9","volume":"7","author":"G Jour","year":"2013","unstructured":"Jour G, West K, Ghali V, Shank D, Ephrem G, Wenig BM (2013) Differential expression of p16(INK4A) and cyclin D1 in benign and malignant salivary gland tumors: a study of 44 Cases. Head Neck Pathol 7(3):224\u2013231. \n                    https:\/\/doi.org\/10.1007\/s12105-012-0417-9","journal-title":"Head Neck Pathol"},{"issue":"2","key":"5058_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4103\/ijdr.IJDR_697_16","volume":"28","author":"RR John","year":"2017","unstructured":"John RR, Malathi N, Ravindran C, Anandan S (2017) Mini review: multifaceted role played by cyclin D1 in tumor behavior. Indian J Dent Res 28(2):187\u2013192. \n                    https:\/\/doi.org\/10.4103\/ijdr.IJDR_697_16","journal-title":"Indian J Dent Res"},{"issue":"3","key":"5058_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.clcc.2016.09.012","volume":"16","author":"Y Liu","year":"2017","unstructured":"Liu Y, Sun H, Hu M, Zhang Y, Chen S, Tighe S, Zhu Y (2017) The role of cyclooxygenase-2 in colorectal carcinogenesis. Clin Colorectal Cancer 16(3):165\u2013172. \n                    https:\/\/doi.org\/10.1016\/j.clcc.2016.09.012","journal-title":"Clin Colorectal Cancer"},{"key":"5058_CR7","doi-asserted-by":"publisher","first-page":"2048731","DOI":"10.1155\/2016\/2048731","volume":"2016","author":"LY Pang","year":"2016","unstructured":"Pang LY, Hurst EA, Argyle DJ (2016) Cyclooxygenase-2: a role in cancer stem cell survival and repopulation of cancer cells during therapy. Stem Cells Int 2016:2048731","journal-title":"Stem Cells Int"},{"issue":"3","key":"5058_CR8","doi-asserted-by":"publisher","first-page":"e0173641","DOI":"10.1371\/journal.pone.0173641","volume":"12","author":"G Yang","year":"2017","unstructured":"Yang G, Deng Q, Fan W, Zhang Z, Xu P, Tang S, Wang P, Wang J, Yu M (2017) Cyclooxygenase-2 expression is positively associated with lymph node metastasis in nasopharyngeal carcinoma. PLoS One 12(3):e0173641. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0173641","journal-title":"PLoS One"},{"issue":"4","key":"5058_CR9","doi-asserted-by":"publisher","first-page":"6003","DOI":"10.18632\/oncotarget.13990","volume":"8","author":"F Xu","year":"2017","unstructured":"Xu F, Li M, Zhang C, Cui J, Liu J, Li J, Jiang H (2017) Clinicopathological and prognostic significance of COX-2 immunohistochemical expression in breast cancer: a meta-analysis. Oncotarget 8(4):6003\u20136012. \n                    https:\/\/doi.org\/10.18632\/oncotarget.13990","journal-title":"Oncotarget"},{"key":"5058_CR10","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1038\/cddis.2011.64","volume":"2","author":"B Liu","year":"2011","unstructured":"Liu B, Wen JK, Li BH, Fang XM, Wang JJ, Zhang YP, Shi CJ, Zhang DQ, Han M (2011) Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms. Cell Death Dis 2:e185. \n                    https:\/\/doi.org\/10.1038\/cddis.2011.64","journal-title":"Cell Death Dis"},{"issue":"3","key":"5058_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3349\/ymj.2011.52.3.445","volume":"52","author":"SW Chae","year":"2011","unstructured":"Chae SW, Sohn JH, Kim DH, Choi YJ, Park YL, Kim K, Cho YH, Pyo JS, Kim JH (2011) Overexpressions of cyclin B1, cdc2, p16 and p53 in human breast cancer: the clinicopathologic correlations and prognostic implications. Yonsei Med J 52(3):445\u2013453. \n                    https:\/\/doi.org\/10.3349\/ymj.2011.52.3.445","journal-title":"Yonsei Med J"},{"issue":"5","key":"5058_CR12","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.3892\/ol.2015.3705","volume":"10","author":"EY Lee","year":"2015","unstructured":"Lee EY, Kang JY, Kim KW (2015) Expression of cyclooxygenase-2, peroxiredoxin I, peroxiredoxin 6 and nuclear factor-\u03baB in oral squamous cell carcinoma. Oncol Lett 10(5):3129\u20133136","journal-title":"Oncol Lett"},{"issue":"12","key":"5058_CR13","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s12032-016-0851-8","volume":"33","author":"MC Solomon","year":"2016","unstructured":"Solomon MC, Vidyasagar MS, Fernandes D, Guddattu V, Mathew M, Shergill AK, Carnelio S, Chandrashekar C (2016) The prognostic implication of the expression of EGFR, p53, cyclin D1, Bcl-2 and p16 in primary locally advanced oral squamous cell carcinoma cases: a tissue microarray study. Med Oncol 33(12):138","journal-title":"Med Oncol"},{"issue":"12","key":"5058_CR14","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.oraloncology.2009.07.016","volume":"45","author":"S Akrish","year":"2009","unstructured":"Akrish S, Peled M, Ben-Izhak O, Nagler RM (2009) Malignant salivary gland tumors and cyclo-oxygenase-2: a histopathological and immunohistochemical analysis with implications on histogenesis. Oral Oncol 45(12):1044\u20131050. \n                    https:\/\/doi.org\/10.1016\/j.oraloncology.2009.07.016","journal-title":"Oral Oncol"},{"issue":"3","key":"5058_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ijom.2009.10.016","volume":"39","author":"Z Tian","year":"2010","unstructured":"Tian Z, Li L, Wang L, Hu Y, Li J (2010) Salivary gland neoplasms in oral and maxillofacial regions: a 23-year retrospective study of 6982 cases in an eastern Chinese population. Int J Oral Maxillofac Surg 39(3):235\u2013242. \n                    https:\/\/doi.org\/10.1016\/j.ijom.2009.10.016","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"3","key":"5058_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ijom.2016.09.021","volume":"46","author":"M Gao","year":"2017","unstructured":"Gao M, Hao Y, Huang MX, Ma DQ, Chen Y, Luo HY, Gao Y, Cao ZQ, Peng X, Yu GY (2017) Salivary gland tumours in a northern Chinese population: a 50-year retrospective study of 7190 cases. Int J Oral Maxillofac Surg 46(3):343\u2013349. \n                    https:\/\/doi.org\/10.1016\/j.ijom.2016.09.021","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"4","key":"5058_CR17","first-page":"947","volume":"22","author":"B Bolat Kucukzeybek","year":"2017","unstructured":"Bolat Kucukzeybek B, Vedat Bayoglu I, Kucukzeybek Y, Alacacioglu A, Yigit S, Akder Sari A, Akyol M, Oktay Tarhan M (2017) The prognostic significance of cyclin D1 expression in patients with triple-negative breast cancer. J BUON 22(4):947\u2013952","journal-title":"J BUON"},{"issue":"9","key":"5058_CR18","doi-asserted-by":"publisher","first-page":"14847","DOI":"10.18632\/oncotarget.14682","volume":"8","author":"B Kumar","year":"2017","unstructured":"Kumar B, Yadav A, Brown NV, Zhao S, Cipolla MJ, Wakely PE, Schmitt AC, Baiocchi RA, Teknos TN, Old M, Kumar P (2017) Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patientsand is inversely associated with p16-status. Oncotarget 8(9):14847\u201314859. \n                    https:\/\/doi.org\/10.18632\/oncotarget.14682","journal-title":"Oncotarget"},{"issue":"2","key":"5058_CR19","doi-asserted-by":"publisher","first-page":"e2603","DOI":"10.1038\/cddis.2016.352","volume":"8","author":"K Qu","year":"2017","unstructured":"Qu K, Wang Z, Fan H, Li J, Liu J, Li P, Liang Z, An H, Jiang Y, Lin Q, Dong X, Liu P, Liu C (2017) MCM7 promotes cancer progression through cyclin D1-dependent signaling and serves as a prognostic marker for patients with hepatocellular carcinoma. Cell Death Dis 8(2):e2603. \n                    https:\/\/doi.org\/10.1038\/cddis.2016.352","journal-title":"Cell Death Dis"},{"issue":"36","key":"5058_CR20","doi-asserted-by":"publisher","first-page":"5219","DOI":"10.1038\/onc.2017.203","volume":"36","author":"J Jen","year":"2017","unstructured":"Jen J, Lin LL, Lo FY, Chen HT, Liao SY, Tang YA, Su WC, Salgia R, Hsu CL, Huang HC, Juan HF, Wang YC (2017) Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer. Oncogene 36(36):5219. \n                    https:\/\/doi.org\/10.1038\/onc.2017.203","journal-title":"Oncogene"},{"issue":"5","key":"5058_CR21","doi-asserted-by":"publisher","first-page":"691696","DOI":"10.1111\/j.1365-2559.2007.02853.x","volume":"51","author":"RS Patel","year":"2007","unstructured":"Patel RS, Rose B, Bawdon H, Hong A, Lee CS, Fredericks S, Gao K, O\u2019Brien CJ (2007) Cyclin D1 and p16 expression in pleomorphic adenoma and carcinoma ex pleomorphic adenoma of the parotid gland. Histopathology 51(5):691\u2013696","journal-title":"Histopathology"},{"issue":"3\u20134","key":"5058_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10911-015-9333-4","volume":"20","author":"HJ Hugo","year":"2015","unstructured":"Hugo HJ, Saunders C, Ramsay RG, Thompson EW (2015) New insights on COX-2 in chronic inflammation driving breast cancer growth and metastasis. J Mammary Gland Biol Neoplasia 20(3\u20134):109\u2013119. \n                    https:\/\/doi.org\/10.1007\/s10911-015-9333-4","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"21","key":"5058_CR23","first-page":"4087","volume":"19","author":"X Zhou","year":"2015","unstructured":"Zhou X, Shi X, Ren K, Fan GT, Wu SJ, Zhao JN (2015) Celecoxib inhibits cell growth and modulates the expression of matrix metalloproteinases in human osteosarcoma MG-63 cell line. Eur Rev Med Pharmacol Sci 19(21):4087\u20134097","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"5058_CR24","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/CMR.0000000000000282","volume":"26","author":"\u0141 Ku\u017abicki","year":"2016","unstructured":"Ku\u017abicki \u0141, Lange D, Stanek-Widera A, Chwirot BW (2016) Intratumoral expression of cyclooxygenase-2 (COX-2) is a negative prognostic marker for patients with cutaneous melanoma. Melanoma Res 26(5):448\u2013456. \n                    https:\/\/doi.org\/10.1097\/CMR.0000000000000282","journal-title":"Melanoma Res"},{"issue":"2","key":"5058_CR25","first-page":"164","volume":"37","author":"RM Whynott","year":"2016","unstructured":"Whynott RM, Manahan P, Geisler JP (2016) Vascular endothelial growth factor (VEGF) and cyclooxygenase 2 (COX 2) immunostaining in ovarian cancer. Eur J Gynaecol Oncol 37(2):164\u2013166","journal-title":"Eur J Gynaecol Oncol"},{"issue":"10","key":"5058_CR26","doi-asserted-by":"publisher","first-page":"10301","DOI":"10.1007\/s13277-014-2260-y","volume":"35","author":"D Wang","year":"2014","unstructured":"Wang D, Guo XZ, Li HY, Zhao JJ, Shao XD, Wu CY (2014) Prognostic significance of cyclooxygenase-2 protein in pancreatic cancer: a meta-analysis. Tumour Biol 35(10):10301\u201310307. \n                    https:\/\/doi.org\/10.1007\/s13277-014-2260-y","journal-title":"Tumour Biol"},{"issue":"2","key":"5058_CR27","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s10620-013-2917-1","volume":"59","author":"J Song","year":"2014","unstructured":"Song J, Su H, Zhou YY, Guo LL (2014) Cyclooxygenase-2 expression is associated with poor overall survival of patients with gastric cancer: a meta-analysis. Dig Dis Sci 59(2):436\u2013445. \n                    https:\/\/doi.org\/10.1007\/s10620-013-2917-1","journal-title":"Dig Dis Sci"},{"issue":"1","key":"5058_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.7314\/APJCP.2012.13.1.315","volume":"13","author":"HM Turk","year":"2012","unstructured":"Turk HM, Camci C, Sevinc A, Bukyukberber S, Sari I, Adli M (2012) Cyclooxygenase-2 expression is not a marker of poor survival in lung cancer. Asian Pac J Cancer Prev 13(1):315\u2013318","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"5058_CR29","doi-asserted-by":"publisher","first-page":"237","DOI":"10.4132\/KoreanJPathol.2012.46.3.237","volume":"46","author":"JW Lee","year":"2012","unstructured":"Lee JW, Park JH, Suh JH, Nam KH, Choe JY, Jung HY, Chae JY, Moon KC (2012) Cyclooxygenase-2 expression and its prognostic significance in clear cell renal cell carcinoma. Korean J Pathol 46(3):237\u2013245. \n                    https:\/\/doi.org\/10.4132\/KoreanJPathol.2012.46.3.237","journal-title":"Korean J Pathol"},{"issue":"5","key":"5058_CR30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1600-0714.2007.00526.x","volume":"36","author":"NP Cho","year":"2007","unstructured":"Cho NP, Han HS, Soh Y, Son HJ (2007) Overexpression of cyclooxygenase-2 correlates with cytoplasmic HuR expression in salivary mucoepidermoid carcinoma but not in pleomorphic adenoma. J Oral Pathol Med 36(5):297\u2013303","journal-title":"J Oral Pathol Med"},{"key":"5058_CR31","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.4049\/jimmunol.173.3.2011","volume":"173","author":"S Shishodia","year":"2004","unstructured":"Shishodia S, Koul D, Aggarwal BB (2004) Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol 173:2011\u20132022","journal-title":"J Immunol"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00405-018-5058-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-018-5058-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-018-5058-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T19:03:34Z","timestamp":1562871814000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00405-018-5058-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,12]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["5058"],"URL":"https:\/\/doi.org\/10.1007\/s00405-018-5058-5","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"type":"print","value":"0937-4477"},{"type":"electronic","value":"1434-4726"}],"subject":[],"published":{"date-parts":[[2018,7,12]]},"assertion":[{"value":"29 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethical approval for this study was obtained from the relevant local ethics committees (CEP\/UPE no 243\/11).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}